Compare NTST & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | PVLA |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2020 | 2013 |
| Metric | NTST | PVLA |
|---|---|---|
| Price | $20.41 | $152.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 15 |
| Target Price | $22.02 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 955.6K | 163.2K |
| Earning Date | 04-20-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | ★ 150.00 | 52.62 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $195,006,000.00 | $42,810,000.00 |
| Revenue This Year | $19.03 | N/A |
| Revenue Next Year | $16.25 | $104,350.18 |
| P/E Ratio | $170.33 | ★ N/A |
| Revenue Growth | 19.79 | ★ 65.28 |
| 52 Week Low | $17.02 | $51.54 |
| 52 Week High | $22.47 | $161.38 |
| Indicator | NTST | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 55.60 |
| Support Level | $20.25 | $135.68 |
| Resistance Level | $20.82 | $160.07 |
| Average True Range (ATR) | 0.31 | 7.73 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 31.65 | 74.08 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.